Spruce Biosciences Overview
Spruce Biosciences (SPRB) has a ROE of -61.33%, below the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow-61.33%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Spruce Biosciences (SPRB) currently reports a ROE of -61.33%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Spruce Biosciences's ROE history and peer comparisons.
Spruce Biosciences's ROE of -61.33% is lower than the Healthcare sector average of 21.67%. That is roughly 383.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Spruce Biosciences's current -61.33% should be judged against Healthcare norms (sector average: 21.67%) and against SPRB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -61.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Spruce Biosciences, and consider following SPRB for alerts when major investors trade the stock.
Spruce Biosciences is classified in the Healthcare sector. On ROE, it currently shows -61.33% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRB with unrelated industries.
